AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-09. Anything still debated is marked as such rather than presented as settled.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
== History == The programme originated in response to protests by dairy farmers in 1984 over surplus unsold milk. To address the issue, the Thai Cabinet established the National Milk Drinking Campaign Board in 1985 and launched a pilot project in Bangkok and Chiang Mai that offered milk at subsidized rates to parents of schoolchildren. Following the success of the pilot, the government introduced a nationwide programme in 1992 to distribute free milk to public schools. The programme significantly contributed to the growth of Thailand’s dairy sector. Annual milk production rose from approximately 290 million litres in the early 1990s to more than 1.1 billion litres by 2003, while per capita milk consumption increased from about 2 litres in 1984 to over 23 litres in 2002. Between 2009 and 2018, competition for milk supply quotas led to various administrative and quality concerns, including reports of spoiled milk and inefficient distribution. In 2019, reforms were introduced to improve transparency and re-establish clear quota zones for suppliers.
Hemp juice is a beverage derived from industrial hemp, made from the result of pressing the Cannabis sativa plant. The juice is obtained through a large-scale industrial cold-pressing procedure using the upper parts of the hemp plant as well as the leaves. This procedure distinguishes hemp juice from other hemp products such as hemp oil, hemp sprouts or hemp milk, which are obtained through the seeds of the hemp plant. Proponents of hemp juice claim it as a base for a variety of drug-free products in the areas of nutrition, medicine, cosmetics, and beverages. Hemp juice has also been used as a flavor enhancer due to its umami flavor. Hemp juice has also appeared as a health food product due to the high amounts of proteins it contains. Studies point out the medical potential of the cannabinoid CBD, which is found in industrial hemp and hemp juice. Drug-free industrial hemp and the hemp juice produced from it offer the advantages of legal cultivation and utilization in many countries, as opposed to the Cannabis Indica and Sativa plants, which have higher tetrahydrocannabinol (THC) content and are not legal in many countries. People have found alternative uses for hemp juice. Hemp juice and its pressed remnants have been used to substitute some portion of flour in bread. It has also been used as a food supplement in the form of freeze-dried hemp juice powder for nutritional reasons, mostly thanks to the high percentage of protein hemp juice possesses.
=== Static function tests === Given the complicated nature of the "clamp" technique (and the potential dangers of hypoglycemia in some patients), alternatives have been sought to simplify the measurement of insulin resistance. The first was the Homeostatic Model Assessment (HOMA), and more recent methods include the Quantitative insulin sensitivity check index (QUICKI) and SPINA-GR, a measure for insulin sensitivity. All of these calculated markers employ fasting insulin and glucose levels to calculate insulin resistance, and all correlate reasonably with the results of clamping studies.
== Biological control of nematodes == This fungus has been investigated as a biocontrol agent of agriculturally important nematodes, most notably those responsible for gastrointestinal infection of grazing animals. These parasitic infections are commonly treated with anthelmintic agents including benimidazole, levamisole and invermectin. However, increasing levels of anthelmintic resistance have been observed, driving the search for new treatment and prevention options. Larvae of animal-pathogenic nematodes are found in soil. The prospect of treating contaminated soils with nematode pathogenic fungi such as H. anguillulae has shown potential to reduce nematode populations. However, the fungus does not persist in soil following the elimination of nematode populations, potentially limiting its use as a sustainable biocontrol agent.
== Controversy == Scientists associated with the initial development of recombinant DNA methods recognized that the potential existed for organisms containing recombinant DNA to have undesirable or dangerous properties. At the 1975 Asilomar Conference on Recombinant DNA, these concerns were discussed and a voluntary moratorium on recombinant DNA research was initiated for experiments that were considered particularly risky. This moratorium was widely observed until the US National Institutes of Health developed and issued formal guidelines for rDNA work. Today, recombinant DNA molecules and recombinant proteins are usually not regarded as dangerous. However, concerns remain about some organisms that express recombinant DNA, particularly when they leave the laboratory and are introduced into the environment or food chain. These concerns are discussed in the articles on genetically modified organisms and genetically modified food controversies. Furthermore, there are concerns about the by-products in biopharmaceutical production, where recombinant DNA result in specific protein products. The major by-product, termed host cell protein, comes from the host expression system and poses a threat to the patient's health and the overall environment.
Sources: en.wikipedia.org
Travis Colyer's profile on the official website of the Fremantle Football Club Travis Colyer's playing statistics from AFL Tables Travis Colyer at AustralianFootball.com Travis Colyer's WAFL playing statistics at WAFLFootyFacts.net
UK-414,495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414,495 acts as a potent, selective inhibitor of the enzyme neutral endopeptidase, which normally serves to break down the neuropeptide VIP. The consequent increase in VIP activity alters blood flow to the genital region leading to increased lubrication and muscle relaxation.
For example, studies have identified TLR4 as the receptor for the LPS component of Gram-negative bacteria. TLRs are key regulators of both innate and adaptive immune responses. Unlike RelA, RelB, and c-Rel, the p50 and p52 NF-κB subunits do not contain transactivation domains in their C terminal halves. Nevertheless, the p50 and p52 NF-κB members play critical roles in modulating the specificity of NF-κB function. Although homodimers of p50 and p52 are, in general, repressors of κB site transcription, both p50 and p52 participate in target gene transactivation by forming heterodimers with RelA, RelB, or c-Rel. In addition, p50 and p52 homodimers also bind to the nuclear protein Bcl-3, and such complexes can function as transcriptional activators.
During the realignment of several conferences within northeastern Wisconsin, eight schools (Berlin, Campbellsport, Kettle Moraine Lutheran, Kewaskum, Plymouth, Ripon, Waupun and Winneconne) joined together to form a new East Central Conference in 2015. Three of the members of the new ECC were also members of the original conference (Berlin, Ripon and Winneconne). In 2021, after a previous unsuccessful attempt two years prior, Campbellsport left the East Central Conference to join the Wisconsin Flyway Conference, leaving the ECC with seven members. That same year, Berlin and Ripon requested a move to the nearby South Central Conference due to declining enrollment and competitive disparity. Winneconne also requested a shift to the Bay Conference due to its growth and West De Pere's desire to move to the larger Fox River Classic Conference. Both requests were denied by the WIAA Task Force due to a lack of solution to move the other four schools. In December 2023, the other four schools requested an exit from the East Central Conference. Kettle Moraine Lutheran wanted to join other private schools in the Midwest Classic Conference, Kewaskum and Plymouth sought membership in the North Shore Conference and Waupun requested a shift to the Capitol Conference. After some deliberation, the decision was made to disband the East Central Conference and disperse its member schools to other conference.
Sources: en.wikipedia.org
=== Neurotoxicity === Dextromethorphan was once thought to cause Olney's lesions when administered intravenously; however, this was later proven inconclusive, due to lack of research on humans. Tests were performed on rats, giving them 50 mg or more every day for as long as a month. Neurotoxic changes, including vacuolation, have been observed in posterior cingulate and retrosplenial cortices of rats administered other NMDA receptor antagonists such as PCP, but not with dextromethorphan.
=== Antiquity === The presence and diseases of the thyroid have been noted and treated for thousands of years. In 1600 BCE burnt sponge and seaweed (which contain iodine) were used within China for the treatment of goitres, a practice which has developed in many parts of the world. In Ayurvedic medicine, the book Sushruta Samhita written about 1400 BCE described hyperthyroidism, hypothyroidism and goitre. Aristotle and Xenophon in the fifth century BCE describe cases of diffuse toxic goitre. Hippocrates and Plato in the fourth century BCE provided some of the first descriptions of the gland itself, proposing its function as a salivary gland. Pliny the Elder in the first century BCE referred to epidemics of goitre in the Alps and proposed treatment with burnt seaweed, a practice also referred to by Galen in the second century, referred to burnt sponge for the treatment of goitre. The Chinese pharmacology text Shennong Ben Cao Jing, written ca. 200–250, also refers to goitre.
=== Conference === WOSM's conference is its general meeting of member organizations' representatives which meet every three years, hosted by a member association. Each member organizations may send six delegates. The conference is usually preceded by the World Scout Youth Forum.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.